Cholesterol gallstone disease is a worldwide common disease. Cholesterol supersaturation in gallbladder bile is the prerequisite for its pathogenesis, while the mechanism is not completely understood. In this study, we find enrichment of gut microbiota (especially Desulfovibrionales) in patients with gallstone disease. Fecal transplantation of gut microbiota from gallstone patients to gallstone-resistant strain of mice can induce gallstone formation. Carrying Desulfovibrionales is associated with enhanced cecal secondary bile acids production and increase of bile acid hydrophobicity facilitating intestinal cholesterol absorption. Meanwhile, the metabolic product of Desulfovibrionales, H2S increase and is shown to induce hepatic FXR and inhibit CYP7A1 expression. Mice carrying Desulfovibrionales present induction of hepatic expression of cholesterol transporters Abcg5/g8 to promote biliary secretion of cholesterol as well. Our study demonstrates the role of gut microbiota, Desulfovibrionales, as an environmental regulator contributing to gallstone formation through its influence on bile acid and cholesterol metabolism.
Cholesterol gallstone disease (GS) is a worldwide prevalent disease, especially in western countries1. Our recent survey found its incidence to be over 12% in Shanghai, China. The prerequisite biochemical disorder leading to gallstone is the formation of cholesterol supersaturated bile in the gallbladder. It is known that both genetic inclination and environmental factors contribute to the pathogenesis of this disease, while the mechanism is not completely understood2. Different strains of mice have different susceptibility to gallstone formation3. Phenotypic changes differed during the process of gallstone formation under lithogenic diet (LD) between strains4,5. In humans, gallstone is prevalent in certain ethnicities, such as Pima Indians and certain pedigrees. The Swedish Twin study demonstrated a heritability of 25% for GS6. On the other hand, non-genetic risk factors as metabolic disorders (i.e., obesity, diabetes mellitus, non-alcoholic fatty liver disease, etc.), were highly connected with gallstone formation7,8,9.
In recent years, the gut microbiota has been recognized to be contributors to metabolic disorders10 such as diabetes mellitus11, obesity12, fatty liver disease13, atherosclerosis14, and others15. The studies also provided evidence that metabolites including short-chain fatty acids, amino acids, produced by the gut microbiota exerted regulatory roles in remote organs as the liver16. These results led us to hypotheses that gut microbiota might play an important role in influencing host gallstone formation. The first clue of the possible involvement of bacteria in gallstone formation could be dated back to an early study decades ago17, in which they showed less incidence of gallstone in germ-free mice. Another study demonstrated that in mice infected with enterohepatic Helicobacter spp. could promote cholesterol gallstones18. However, there is a lack of enough evidence to explore the mechanisms for gut microbiota contributing to gallstone formation.
In this study, we identified enrichment of Desulfovibrionale in feces from patients with cholesterol GS as well as in gallstone-susceptible mice. By fecal microbiota transplantation (FMT) from gallstone patients or by co-housing with gallstone-susceptible mice, gallstone formation could be induced in gallstone-resistance mice. We further demonstrated that carrying Desulfovibrionale was related to an increase of secondary bile acid production due to activated bile acid dehydroxylation of gut microbiota, leading to an increase of bile acid hydrophobicity which facilitated intestinal cholesterol absorption, resulting in hepatic accumulation of cholesterol and enhancement of biliary cholesterol secretion.
Enrichment of Desulfovibrionales in patients with cholesterol GS
Feces samples from 80 patients with cholesterol GS and 49 gallstone-free controls (GSF) were collected. The fecal microbiota composition of both groups was analyzed by 16s rRNA sequencing. The microbiota composition showed a higher abundance of Desulfovibrionales order in GS patients than in GSF controls (Fig. 1A), which suggested an association between Desulfovibrionales and gallstone susceptibility.
Desulfovibrionales enriched human FMT induced gallstone formation in gallstone-resistant mice
Donor feces enriched in Desulfovibrionales from gallstone patients (GS) or feces from gallstone-free (GSF) controls were transplanted to gallstone-resistant AKR/J mice (GS-R mice). No gallstone formed in mice subjected to transplantation of feces from GSF controls (0/12) after 8-week LD. Desulfovibrionales were not detected in these mice. However, gallstone formed in 73% (8/11) of the mice receiving feces from the GS donors (Fig. 1B). The profiles of gut microbiota suggested the successful introduction of Desulfovibrionales to these mice (Fig. 1C). Biliary composition analysis showed the increased cholesterol molar and cholesterol saturation index (CSI) (Fig. 1D) in the gallbladder bile in mice carrying Desulfovibrionales. Serum high-density lipoprotein, low-density lipoprotein cholesterol (Fig. S1A), and hepatic cholesterol (Fig. S1B) levels were higher as well. The results demonstrated that Desulfovibrionales from gallstone patients were capable to induce gallstone formation.
Introducing Desulfovibrionales to gallstone-resistant mice by co-housing with gallstone susceptible-mice promoted gallstone formation
Comparing the gut microbiota between the gallstone-susceptible mice C57BL/6J (GS-S mice), and the gallstone-resistant mice AKR/J (GS-R mice), we found that Desulfovibrionales order was also markedly abundant in C57BL/6J mice (Fig. 2A) as well as shown by LEfSe algorithm (Fig. 2B and Fig. S2). Desulfovibrio fairfieldensis, piger, desulfuricans, and vulgaris were identified to be the major species (Fig. 2C) in GS-S mice, which were barely detected in GS-R mice.
Co-housing (Fig. 3A) successfully modified the gut microbiota in GS-R mice from the original mice (Fig. 3B) with significant enrichment of Desulfovibrionales order in the co-housing GS-R mice (Fig. 3D). As a result, gallstone formation increased to 70% in co-housing GS-R mice (Fig. 3A). Profiles of gallbladder bile composition from co-housing GS-R mice turned to resemble GS-S mice, presenting as elevated biliary cholesterol molar percentage and CSI (Fig. 3C), a condition favoring gallstone formation.
Carrying Desulfovibrionales influenced bile acid profiles
A major role of Desulfovibrionales is to reduce substrates such as taurine into H2S, which was reported to be a necessary grow factor for 7α-dehydroxylating bacteria19. Interestingly, comparing the multi-gene BA-inducible (Bai) operon encoding genes involved in 7-α/β dehydroxylation of BAs (Fig. 4A), we found that GS-S mice had higher expression of BaiB, CD, and F (Fig. 4B), indicating an active bile acid dehydroxylation in these mice. Accordingly, 7α-dehydroxylation activity in the cecum content was significantly higher in GS-S mice as well as GS-R mice after co-housing (Fig. 4C).
Next, we measured the cecal bile acids. As expected, DCA, the product of bacteria 7a-dehydroxylation and the major component of cecal bile acids, was significantly higher in GS-S mice and co-housing GS-R mice (Fig. 4D).
In gallbladder bile, cholic acid (CA) and DCA, comprised >97% of the total bile acids in GS-S mice (Fig. 4E and Fig. S3A–C). However, GS-R mice retained a considerable amount of hydrophilic bile acids: β-muricholic acid (βMCA), αMCA, and ursodeoxycholic acid (UDCA) in their bile (≈25%), but less hydrophobic DCA. Co-housing led to a 50% decrease of βMCA and an 18% increase of CA in GS-R mice (Fig. 4E and Fig. S3C). The hydrophobicity index (HI) of bile acids was significantly higher in GS-S mice and co-housing GS-R mice (Fig. 4F).
Furthermore, GS-R mice receiving FMT from the gallstone patients also had higher cecal 7α-dehydroxylation activity (Fig. S4A), indicating a similar enhancement of secondary bile acids conversion. In line with this, DCA and ωMCA were higher, but βMCA, αMCA, and UDCA were lower in gallbladder bile (Fig. S4B, C), leading to higher HI in these mice (Fig. S4D).
These data collectively indicated that introducing Desulfovibrionales to GS-R mice led the bile acid profile to be more hydrophobic.
Influences on hepatic transcripts of bile acid and cholesterol metabolism in mice carrying Desulfovibrionales
To further unravel the impacts of Desulfovibrionale on the hepatic metabolic disorders in promoting gallstone formation, we performed RNA-seq in liver samples from mice in the co-housing experiment (Fig. 5A). Co-housing could further repress the expression of genes related to bile acid synthesis in GS-R mice, especially the expression of the rate-limiting enzymes of bile acid synthesis—cholesterol 7α-hydroxylase (Cyp7a1), the enzyme responsible for cholic acid synthesis—Cyp8b1. qRT-PCR further validated the inhibition of their expression in AKR/J mice after co-housing (Fig. 5B).
The gene expression profile in hepatic cholesterol metabolism was also changed (Fig. 5A). 3α-hydroxy-3-methyl-glutarylcoenzeme A (Hmgcr), the rate-limiting enzyme for cholesterol synthesis, was higher in GS-S mice even under conditions when cholesterol was overloading (Fig. 5A, B). The expression of Hmgcr elevated in GS-R mice after co-housing. The expressions of hepatic cholesterol transporters, ATP binding cassette (Abc) g5 and Abcg8, were elevated GS-R mice after co-housing (Fig. 5A, B).
In the GS-R mice receiving FMT from gallstone patients, similar changes of genes in bile acid and cholesterol metabolism could be observed after carrying Desulfovibrionales (Fig. 5C).
The product of Desulfovibronales regulated hepatic FXR-CYP71 expression
Desulfovibrionales contains genes for sulfate reduction to reduce sulfate to H2S. In GS-S mice (C57BL/6J) had significantly higher serum H2S than GS-R mice (AKR/J) and co-housing led to an increase of serum H2S in GS-R mice (Fig. 6A). H2S was reported to enhance FXR expression in HepG2 cells20, which in turn inhibited CYP7A1 expression21. To collaborate this, we treated mice with GYY4137, a novel H2S donor releasing H2S slowly and mimicking the time course of H2S release in vivo22. We found GYY4137 increased FXR protein and decreased CYP7A1 protein in liver tissues (Fig. 6B). Furthermore, both in the murine hepatocyte, Hepa1-6 (Fig. 6C), and human hepatoma cells, HuH7 (Fig. 6D), a dose-dependent induction of FXR and inhibition of CYP7A1 expression was found. These data suggested the existence of a regulatory pathway of hepatic bile acid metabolism by Desulfobibronale through its product H2S.
Species of Desulfovibro promoted gallstone formation in mice
To further validate the role of Desulfovibrio species on gallstone formation, we transplanted three commercially available species of Desulfovibrio piger, desulfuricans, and vulgaris to antibiotics-pre-treated GS-S mice. Depletion of gut microbiota decreased the gallstone incidence to 70% (7/10). In contrast, Desulfovibrio species transplantation restored gallstone incidence to 100% (10/10, Fig. 7A). Similarly, Desulfovibrio species transplantation could induce gallstone formation in 42% (5/12) of the GS-R mice (Fig. S5A), whereas none of the control GS-R mice formed gallstone (0%).
In the Desulfovibrio species transplantation group of mice, serum and hepatic cholesterol levels were significantly elevated in the transplanted mice (Fig. 7B, C). Moreover, expressions of genes in hepatic bile acid synthesis, Cyp7a1, Cyp8b1, Cyp27, and Cyp2c70 were inhibited, and the expressions of Abcg5, Abcg8, Srb1, and Hmgcr were elevated (Fig. 7D and Fig. S5B).
To monitor the influence of Desulfovibrio species on the hepatic secretion of biliary lipids, hepatic bile was collected by common bile duct cannulation. In mice with Desulfovibrio species transplantation, a significant increase of cholesterol and phospholipids but less bile acid output in their hepatic bile was observed (Fig. 7E). This result suggested that carrying Desulfovibrio species promoted the hepatic secretion of cholesterol into bile.
The present study provided evidence that Desulfovibrionales-enriched gut microbiota contributed to gallstone formation through the mechanisms as graphically shown in Fig. 8: the gallstone-prone microbiota could (1) induce cecal bacterial 7α-dehydroxylase activities to produce more secondary bile acids; (2) produce H2S which could induce hepatic FXR and inhibit CYP7A1 expression and bile acid synthesis, (3) these collectively, modulate hepatic bile acid metabolism to produce more hydrophobic bile acids due to increased DCA and decreased βMCA, which increases HI of bile acids facilitating intestinal cholesterol absorption (4) resulting in hepatic cholesterol overloading, and thereafter (5) promoting canalicular cholesterol secretion into bile and gallstone formation.
The gut microbiota enriched in Desulfovibrionales was capable to modulate bile acid profiles to be more hydrophobic. Desulfovibrionales are responsible for metabolizing dietary and host-derived sulfur-containing compounds23. Taurine is a source of sulfur-containing substance and Desulfovibrionale-derived H2S could favor the growth of 7α-dehydroxylating bacteria growth19. A similar need for taurine as a growth-stimulating factor that is completely reduced to H2S has been demonstrated for other intestinal bacteria24. In line with this, we found in mice enriched in Desulfovibrionales (human FMT and co-housing mice), the activities of 7α-dehydroxylation were all higher. Accordingly, these mice had more secondary bile acids production as well. The other reported gut bacteria containing bile salt hydrolase activity included Clostridium, Bifidobacterium, and Lactobacillus25. Free bile acids are sequentially converted to secondary bile acids mediated by 7α-dehydroxylation reaction catalyzed by some species of Clostridium. However, no significant difference of species of Clostridium was found among groups of mice. Barely any Bifidobacterium and Lactobacillus were detected in any strain of mice under LD due to the inhibition of their growth by bile acids as DCA26. This is also in line with similar activities of bile salt hydrolase among groups. An increase in Desulfovibrionales has been described in mice fed with a high-fat diet as well27,28. These bacteria contain genes for sulfate reduction to reduce sulfate to H2S, damaging the gut barrier29 and producing endotoxins30 and pro-inflammatory cytokines such as IL631,32. Furthermore, in the present study, we showed that H2S was capable to regulate hepatic bile acid metabolism by induction of FXR and inhibition of CYP7A1. This regulatory pathway has been proposed previously in HepG2 cells20,21. Here, we further collaborated the presence of such regulatory pathway in mice in vivo as well as in cell lines in vitro.
Furthermore, the gut microbiota might play a role to modulate bile acid synthesis in the liver by alleviating FXR inhibition through TβMCA, a reported FXR antagonist33. In single housing GS-R mice, Cyp7a1 was less inhibited due to the presence of considerable TβMCA33. After human FMT or co-housing introducing Desulfovibrionales to GS-R mice, these mice had a similar bile acid profile with GS-S mice and hepatic Cyp7a1 expression was reduced accordingly. The alteration of cecal and hepatic bile acid metabolism thus resulted in the elevation of HI of bile acids which could augment intestinal cholesterol absorption, hepatic cholesterol overloading, and biliary cholesterol output34.
Cholesterol overloading is not only due to exogenous cholesterol absorption, but de novo cholesterol synthesis as well. In GS-S mice, hepatic cholesterol de novo synthesis retained high as we observed, which is in line with the previous findings4,35. In human FMT or co-housing gallstone-resistant mice, expressions of key enzymes, Hmgcr, Fdps, Sqle, were less inhibited suggesting the maintenance of higher hepatic cholesterol synthesis in these mice even under cholesterol overloading. Furthermore, bile acid synthesis is one way to degrade cholesterol. The more inhibition of bile acid synthesis could also partly account for the more accumulation of cholesterol in the liver in mice carrying gut microbiota Desulfovibrionale.
Excessive hepatic cholesterol, in turn, could upregulate canalicular cholesterol transporters Abcg5/g8 via activation of LXRα and enhance biliary cholesterol secretion36. In all mice carrying gut microbiota Desulfovibrionale by FMT or co-housing, the expression levels of Abcg5/g8 were induced and correlated with higher biliary cholesterol molar percentage. Induction of hepatic secretion of cholesterol further collaborated in mice transplanted with species of Desulfovibrio. This indicated a potential activation of LXRα on Abcg5/g8 in mice carrying Desulfovibrio species.
In conclusion, in this study, we demonstrated that carrying Desulfovibronales promoted gallstone formation. The gallstone-prone microbiota was able to induce gallstone formation by modulating bile acid hydrophobicity and promoting biliary cholesterol secretion. The results of our present study evoked our awareness of gut microbiota participating in the regulation of enterohepatic bile acid and cholesterol metabolism in promoting cholesterol gallstone formation.
All the study protocols for research animals and human study participants were approved by the Ethical Committee at Shanghai East Hospital, Tongji University School of Medicine (EC. D (BG). 016. 02.1 (2017-027)). Written informed consent was obtained from patients who provided their feces samples.
Reagents used in the study are listed in Supplementary Table 1.
Feces samples were provided by patients who underwent laparoscopic cholecystectomy due to GS (GS, n = 80) or gallstone-free volunteers who underwent health examination (GSF, n = 49). Only the patients with cholesterol type of gallstone were included by classification as typical cholesterol by visual inspection of cut-surface of gallstones and when necessary, by chemical analysis in the laboratory37,38. All the controls were confirmed to be gallstone-free by B-type ultrasonography. Subjects who had been taken antibiotics during the past 3 months prior to sampling were excluded. Subjects with metabolic disorders, such as obesity, diabetes mellitus, hyperlipidemia, or chronic bowel disease, or chronic diarrhea, or constipation, were also excluded.
Male C57BL/6J mice were bought from Shanghai SLAC Laboratory Animal Company Ltd. (Shanghai, China) and AKR/J mice from Jackson Laboratory (Bar Harbor, ME, USA). Male mice (at age of 7–8 weeks) were fed with LD (containing 1.25% cholesterol and 0.5% cholic acid, synthesized by Trophic Animal Feed High-Tech Co. Ltd, Nantong, China) for 8 weeks before sacrifice. The mice were bred at the Animal Care Facility on a 12-h light/12-h dark cycle in a controlled temperature (22.5 ± 2.5 °C) and humidity (50 ± 5%) environment.
In human fecal microbiota transplantation (HuFMT) study, AKR/J mice were orally gavaged with donor human feces (dissolved in phosphate-buffered saline (PBS) 1.5 ml/200 mg of feces weight) once after depletion of gut microbes by antibiotics cocktails (containing 0.5 g/l vancomycin, 1 g/l neomycin sulfate, 1 g/l metronidazole, 1 g/l ampicillin39) in drinking water ad libitum for 3 weeks after weaning (at the age of 4 weeks). Donor feces were selected from the patient cohort in result 1 (Fig. 1A). The gallstone-patient donors were the 3 patients whose feces were the top 3 with enrichment of Desulfovibrionales as determined by 16s rRNA sequencing and GSF donors were 3 gallstone-free subjects whose feces had no detection of Desulfovibrionales. Feces sample from each donor was gavaged to 4 recipient mice (1 donor: 4 recipient mice). All mice were then fed with LD for 8 weeks (one mouse in the FMT from the gallstone patient donor group died after gavage).
In the co-housing study, AKR/J mice were given a cocktail of antibiotics for 3 weeks after weaning. Afterward, the AKR/J mice were co-housing with conventional C57BL/6 mice at a ratio of 1:1 for 1-week and then fed with LD for 8 weeks.
In bacteria inoculation study, Desulfovibrio vulgaris (ATCC-29579), Desulfovibrio desulfuricans (ATCC-29577), and Desulfomonas pigra (ATCC-29098) were purchased from ATCC, and cultured in anaerobically sterilized ATCC medium 1249 under strict anaerobic conditions overnight. C57BL/6J or AKR/J mice were depleted of gut microbes by antibiotics cocktails for 3 weeks after weaning and then oral gavaged with sterile PBS or live mixed Desulfovibrio (1:1:1) at a dose of 5 × 108 colony forming units/100 μl in sterile PBS, respectively, three times a week for 4 weeks. Upon starting of gavage, mice were fed with LD for 8 weeks. After 4-week feeding, bile duct cannulation was performed in a subset of mice according to the procedure as described40. In brief, the common bile duct of mice fasted overnight was ligated and the common bile duct was cannulated with a PE-10 polyethylene catheter below the entrance of the cystic duct. The cystic duct was doubly ligated and a cholecystectomy was performed and the first-hour hepatic bile was collected.
In exogenous H2S study, 8-week-old C57BL/6J male mice were administered with either vehicle alone (normal saline) or vehicle containing GYY4137 (133 μmol/kg/day) (Cat No.B7458, APExBIO Technology, Houston, USA) for 7 days by intraperitoneal injection. GYY4137 is a novel H2S donor that could release H2S slowly and mimic the time course of H2S release in vivo22.
All mice were fasted 8 h before sacrifice. The blood sample was obtained by heart puncture. Liver, gallbladder, intestine, and cecal contents were collected and stored at −80 °C under analysis.
Cell culture and experiment conditions
Mouse hepatocytes, Hepa1-6 cells, were cultured in Dulbecco’s Modified Eagle Medium (DMEM)-high glucose (Cat No. 12430054, Gibco, New York, USA) supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate (Cat No. 11360070, Gibco, New York, USA). Human hepatoma cells, HuH-7 cells, were cultured in DMEM-high glucose (Cat No. 11960044, Gibco, New York, USA) supplemented with 10% FBS, 1 mM sodium pyruvate (Cat No. 11360070, Gibco, New York, USA), and GlutaMAX™ (Cat No. 35050061, Gibco, New York, USA). Cells with 80–85% confluence were incubated with or without GYY4137 (300 or 600 μM) and GW4064 (5 μM) (Cat No. B1527, APExBIO Technology, Houston, USA).
Analysis of biliary lipids
Total bile acids, phospholipids, and cholesterol concentration in the gallbladder or hepatic bile were measured by enzymatic methods as previously described38,41 using commercial purchased kits (cholesterol: Cat No. 11491458216, from Roche Diagnostics GmbH, Germany; total bile acids: Cat No. BI2672 from RANDOX, UK; and phospholipids: phospholipid LabAssay kit, Cat No. WAKO 296-63801, from Fuji Film WAKO Pure Chemical Co, Japan). The relative concentrations of biliary lipids were expressed as molar percentages of the total biliary lipids. The CSI was calculated according to Carey’s critical table42.
Twenty-five microliters of serum were diluted and analyzed for cholesterol level on HITACHI automated biochemical analyzer. Lipids in liver tissue (50 mg) were extracted by chloroform:methanol solution (2/1, v/v), and total cholesterol levels were determined by enzymatic kit as previously described43. Serum campesterol and β-sitosterol levels were measured by gas-liquid chromatography-mass spectrometry as described44.
Measurement of H2S level in serum
Serum H2S was assayed by spectrophotometry as described45. Briefly, 75 μl serum was reacted with 250 μl zinc acetate (1%), 425 μl distilled water, N,N-dimethyl-p-phenylenediamine sulfate in 7.2 M HCl (133 μl, 20 mM) and FeCl3 in 1.2 mM HCl (133 μl, 30 mM). The sample was incubated at room temperature for 10 min and then the reaction was stopped by adding 10% v/v trichloroacetic acid (250 μl). After centrifugation, the absorption of the supernatant was measured at 670 nm by spectrophotometry. NaHS (2.5–200 μM) was used as a standard.
Bile acid analysis
Gallbladder bile, liver tissue homogenates, or cecal content were diluted with internal standard, vortexed, and purified by the sedimentation plate. Samples were then lyophilized and dissolved with 25% acetonitrile. After centrifugation, the supernatants were collected for measuring the levels of various bile acids. Bile acids profiles were analyzed on an Acquity UPLC system coupled to a Waters Xevo TQ-S MS (Waters, Manchester, UK), equipped with a C18 reverse-phase column with 1.7 mm particle size (Waters Corp., Milford, MA, USA). Analytes were detected by electrospray ionization and quantified by internal standard methods as described46. The HI of bile acids in gallbladder bile was calculated as described47.
Gut flora activity assays
Activities of the gut flora were measured according to the procedure as described48,49. One gram of cecal contents of each mouse was dissolved in 3 ml sterilized solution A (containing 20 % glycerol and 1.8 % sodium chloride) which was diluted in polyPeptone Yeast Extract Medium (PY culture medium) and then cultured at 37 °C and 200 rpm for 12 h to allow anaerobic bacteria to proliferate. Afterward, 200 μl tauro-cholic acid (200 μg/ml) was added in 1 ml the mixture and incubated for another 1 h at 37 °C in the anaerobic chambers and the reaction was stopped by 100 μl of 1 M HCl. The generation of cholic acid and deoxycholic acid were measured by Acquity UPLC system coupled to a Waters Xevo TQ-S MS for the calculation of gut flora activities.
Total genomic bacterial DNA was extracted from cecal samples using the QIAamp Fast DNA Stool Mini Kit (Qiagen, Germany) following the manufacturer’s instructions. PCR amplification of bacteria DNA was performed as previously described46. Amplicons were extracted from 2% agarose gel, purified by the AxyPrep DNA gel extraction kit (Axygen Biosciences, Union City, CA, USA), and quantified by QuantiFluorTM-ST (Promega, Madison, WI, USA) according to the manufacturer’s protocols. Then purified amplicons were pooled in equimolar amounts and paired-end sequenced on an Illumina MiSeq platform following standard instructions by the commercial service of Genergy Biotechnology Co. Ltd. (Shanghai, China).
Raw Illumina fasta files were de-multiplexed, quality filtered, and analyzed using the QIIME software according to standardized criteria as described50. Operational taxonomic units (OTUs; 97% sequence similarity) were clustered using the UPARSE software (version 7.1, http://drive5.com/uparse/), and chimeric sequences were identified and removed using the UCHIME program. The phylogenetic affiliation of each 16S rRNA gene sequence was analyzed using the Ribosomal Database Project Classifier tool (version 11.1, http://rdp.cme.msu.edu/) against the SILVA (SSU115) 16S rRNA database (http://www.arb-silva.de) using a confidence threshold of 70%. Alpha diversity was used to describe the microbial richness, diversity, and evenness within samples with four parameters: two richness estimators (Chao1 and the abundance-based coverage estimator) and two diversity indices (Shannon and Simpson indices). Jackknifed beta diversity analysis (between-sample diversity comparisons) was calculated using weighted and unweighted unifrac distances between samples, and principal coordinates were also computed to compress dimensionality into two-dimensional principal coordinate analysis plots. Observed species alpha rarefaction of filtered OTU tables was also performed to confirm that the sequence coverage was adequate to capture the species diversity observed in all samples. Identification of microbial genes involved in BA biotransformation was performed using methods as reported51.
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA quality was examined by gel electrophoresis and with a Nanodrop spectrophotometer (Thermo, Waltham, MA, USA). cDNA library generation with the TruSeqRNA Sample Preparation Kit (Illumina, San Diego, CA, USA). Clusters were generated with the TruSeq SR Cluster Kit v2 according to the reagent preparation guide.
The RNA sequencing was performed using the HiSeq X Ten platform by the commercial service of Genergy Biotechnology Co. Ltd. (Shanghai, China). The raw data was handled by Perl and data quality was checked by FastQC 0.11.2 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). RNA-Seq reads were aligned to the reference data downloaded from UCSC (version hg19), and the RPKM method was utilized to normalize the reads that exclusively mapped to a gene, to quantify the transcript levels52.
Western blot analysis
Total protein from frozen livers or cultured cells were extracted and used with western immunoblotting as described previously53. The following antibodies were used for western blot: anti-FXR (1:1000, Abcam, ab235094), anti-CYP7A1 (1:1000, Abcam, ab65596), anti-CYP8B1 (1:1000, Abcam, ab191910), anti-GAPDH (1:1000, Proteintech, 60004-1-Ig). Images were quantified using the Image Pro Plus 6.0 software.
Quantitative real-time PCR
Power Mix Sybr Green Master Mix (Applied Biosystems) was used for quantitative real-time PCR to determine the target gene expressions. The relative mRNA expression was calculated with the ΔΔCt method using GAPDH as the internal control as described43. Primer sequences are listed in Supplementary Table 1.
Quantitative data are expressed as mean ± SEM and qualitative data as a ratio. The difference between the two groups was compared by t test and among multiple groups by analysis of variance followed by least significant difference test for post hoc analysis between the groups. Two-sided P < 0.05 was regarded as statistical significance. All the statistics were performed using the SPSS 12.0 software.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
All the data are available upon request. The raw data of 16s rRNA sequencing generated in this study has been deposited at NCBI SRA BioProject (accession no: PRJNA773136) and that of RNA-seq at EMBL-EBI (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8550). Source data are provided with this paper.
Scripts for plots under python are available at the website https://github.com/zhajia2019/Python_Scripts.
Di Ciaula, A., Wang, D. Q. & Portincasa, P. An update on the pathogenesis of cholesterol gallstone disease. Curr. Opin. Gastroenterol. 34, 71–80 (2018).
Rebholz, C., Krawczyk, M. & Lammert, F. Genetics of gallstone disease. Eur. J. Clin. Investig. 48, e12935 (2018).
Lammert, F., Carey, M. C. & Paigen, B. Chromosomal organization of candidate genes involved in cholesterol gallstone formation: a murine gallstone map. Gastroenterology 120, 221–238 (2001).
Lammert, F., Wang, D. Q., Paigen, B. & Carey, M. C. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: integrated activities of hepatic lipid regulatory enzymes. J. Lipid Res. 40, 2080–2090 (1999).
van Erpecum, K. J. et al. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: soluble pronucleating proteins in gallbladder and hepatic biles. J. Hepatol. 35, 444–451 (2001).
Katsika, D. et al. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 41, 1138–1143 (2005).
Wang, F. et al. Gallstone disease and type 2 diabetes risk: a Mendelian randomization study. Hepatology 70, 610–620 (2018).
Liu, T. et al. Association between different combination of measures for obesity and new-onset gallstone disease. PloS one 13, e0196457 (2018).
Arrese, M., Cortes, V., Barrera, F. & Nervi, F. Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship. Curr. Opin. Gastroenterol. 34, 90–96 (2018).
Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–846 (2006).
Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60 (2012).
Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2009).
Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179–185 (2012).
Komaroff, A. L. The microbiome and risk for atherosclerosis. JAMA 319, 2381–2382 (2018).
Sonnenburg, J. L. & Backhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature 535, 56–64 (2016).
Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S. & Jalan, R. Targeting the gut-liver axis in liver disease. J. Hepatol. 67, 1084–1103 (2017).
Frey, C., Thorpe, C. & Abrams, G. Gallstone formation in the germ-free mouse. Am. J. Surg. 115, 75–81 (1968).
Maurer, K. J. et al. Identification of cholelithogenic enterohepatic helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology 128, 1023–1033 (2005).
Van Eldere, J., Celis, P., De Pauw, G., Lesaffre, E. & Eyssen, H. Tauroconjugation of cholic acid stimulates 7 alpha-dehydroxylation by fecal bacteria. Appl. Environ. Microbiol. 62, 656–661 (1996).
Qu, K. et al. H2 S inhibits apo(a) expression and secretion through PKCalpha/FXR and Akt/HNF4alpha pathways in HepG2 cells. Cell Biol. Int. 40, 906–916 (2016).
Chow, M. D., Lee, Y. H. & Guo, G. L. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol. Asp. Med. 56, 34–44 (2017).
Li, L. et al. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation 117, 2351–2360 (2008).
Peck, S. C. et al. A glycyl radical enzyme enables hydrogen sulfide production by the human intestinal bacterium Bilophila wadsworthia. Proc. Natl Acad. Sci. USA 116, 3171–3176 (2019).
Van Eldere, J., Robben, J., De Pauw, G., Merckx, R. & Eyssen, H. Isolation and identification of intestinal steroid-desulfating bacteria from rats and humans. Appl. Environ. Microbiol. 54, 2112–2117 (1988).
Ridlon, J. M., Harris, S. C., Bhowmik, S., Kang, D. J. & Hylemon, P. B. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7, 22–39 (2016).
Kurdi, P., Kawanishi, K., Mizutani, K. & Yokota, A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J. Bacteriol. 188, 1979–1986 (2006).
Hildebrandt, M. A. et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137, 1716.e1-2–1724.e1-2 (2009).
Zhang, C. et al. Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J. 6, 1848–1857 (2012).
Beerens, H. & Romond, C. Sulfate-reducing anaerobic bacteria in human feces. Am. J. Clin. Nutr. 30, 1770–1776 (1977).
Loubinoux, J., Mory, F., Pereira, I. A. & Le Faou, A. E. Bacteremia caused by a strain of Desulfovibrio related to the provisionally named Desulfovibrio fairfieldensis. J. Clin. Microbiol. 38, 931–934 (2000).
Weglarz, L. et al. Biological activity of Desulfovibrio desulfuricans lipopolysaccharides evaluated via interleukin-8 secretion by Caco-2 cells. Scand. J. Gastroenterol. 38, 73–79 (2003).
Weglarz, L. et al. Desulfovibrio desulfuricans lipopolysaccharides induce endothelial cell IL-6 and IL-8 secretion and E-selectin and VCAM-1 expression. Cell. Mol. Biol. Lett. 8, 991–1003 (2003).
Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225–235 (2013).
Wang, D. Q., Tazuma, S., Cohen, D. E. & Carey, M. C. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G494–G502 (2003).
Khanuja, B. et al. Lith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice. Proc. Natl Acad. Sci. USA 92, 7729–7733 (1995).
Dikkers, A., Freak de Boer, J., Annema, W., Groen, A. K. & Tietge, U. J. Scavenger receptor BI and ABCG5/G8 differentially impact biliary sterol secretion and reverse cholesterol transport in mice. Hepatology 58, 293–303 (2013).
Fu, P. B. et al. [Morphological structure of the hemisection surface and chemical composition of biliary calculi]. Bull. Acad. Natl Med. 167, 605–612 (1983).
Gustafsson, U., Sahlin, S. & Einarsson, C. Biliary lipid composition in patients with cholesterol and pigment gallstones and gallstone-free subjects: deoxycholic acid does not contribute to formation of cholesterol gallstones. Eur. J. Clin. Investig. 30, 1099–1106 (2000).
Gregory, J. C. et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J. Biol. Chem. 290, 5647–5660 (2015).
Wang, D. Q., Lammert, F., Paigen, B. & Carey, M. C. Phenotypic characterization of lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice. Pathophysiology of biliary lipid secretion. J. Lipid Res. 40, 2066–2079 (1999).
Wang, J. et al. Studies on LXR- and FXR-mediated effects on cholesterol homeostasis in normal and cholic acid-depleted mice. J. Lipid Res. 47, 421–430 (2006).
Carey, M. C. Critical tables for calculating the cholesterol saturation of native bile. J. Lipid Res. 19, 945–955 (1978).
Jiang, Z. Y. et al. Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients. J. Lipid Res. 49, 464–472 (2008).
Jiang, Z. Y. et al. Increased NPC1L1 and ACAT2 expression in the jejunal mucosa from Chinese gallstone patients. Biochem. Biophys. Res. Commun. 379, 49–54 (2009).
Liu, Z. et al. The hydrogen sulfide donor, GYY4137, exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E(-/-) mice. Br. J. Pharmacol. 169, 1795–1809 (2013).
Liu, Q. et al. Organochloride pesticides modulated gut microbiota and influenced bile acid metabolism in mice. Environ. Pollut. 226, 268–276 (2017).
Heuman, D. M. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J. Lipid Res. 30, 719–730 (1989).
Zhao, C. et al. An in vitro metabolic system of gut flora and the metabolism of ginsenoside Rg3 and cholic acid. Eur. J. Drug Metab. Pharmacokinet. 39, 129–137 (2014).
Sun, R. et al. Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway. Mol. Pharmacol. 91, 110–122 (2017).
Wang, Q. et al. Alteration of gut microbiota in association with cholesterol gallstone formation in mice. BMC Gastroenterol. 17, 74 (2017).
Gu, Y. et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat. Commun. 8, 1785 (2017).
Sun, H. et al. Berberine ameliorates blockade of autophagic flux in the liver by regulating cholesterol metabolism and inhibiting COX2-prostaglandin synthesis. Cell Death Dis. 9, 824 (2018).
Shao, W. et al. Early-life perfluorooctanoic acid exposure induces obesity in male offspring and the intervention role of chlorogenic acid. Environ. Pollut. 272, 115974 (2021).
This work was supported by the National Natural Science Foundation of China (91839102, U21A20340, 82070654, 81770626, 81770625, 82121001); the National Key R&D Program of China (2019YFA0802701), The Featured Clinical Discipline Project of Shanghai Pudong (PWYts2021-06).
The authors declare no competing interests.
Peer review information
Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hu, H., Shao, W., Liu, Q. et al. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion. Nat Commun 13, 252 (2022). https://doi.org/10.1038/s41467-021-27758-8
This article is cited by
BMC Gastroenterology (2023)
AQP3-mediated activation of the AMPK/SIRT1 signaling pathway curtails gallstone formation in mice by inhibiting inflammatory injury of gallbladder mucosal epithelial cells
Molecular Medicine (2023)
Dietary diosgenin transcriptionally down-regulated intestinal NPC1L1 expression to prevent cholesterol gallstone formation in mice
Journal of Biomedical Science (2023)
Science China Life Sciences (2023)
Roles of ursodeoxycholic acid in the bile biochemistry and metabolomics in patients with choledocholithiasis: a prospective study